Incomplete data on molecular markers such as HER2, MMR status and PD-L1 expression, particularly the unexplored association between PD-L1 expression levels and the therapeutic efficacy of immunotherapy in young GC patients, may introduce bias into the study outcomes. This evidence concerns the gene ERBB2 and gastric cancer.